GestVision is a biotechnology company that is committed to securing safer pregnancies by fearlessly challenging the status quo for women’s health. We promise to deliver confidence to healthcare providers to make sound clinical decisions. Our aim is to address the unmet medical needs in women’s health by bringing forth premium products based upon robust scientific discoveries.

GestVision-Leadership Team
Translating science into lifesaving tools

  • Wendy L. Davis, MBA

    Founder and Chief Executive Officer
    Wendy is the Founder and CEO of GestVision. Wendy has over 30 years’ experience in biotechnology cultivating novel opportunities from early stage inventions through commercialization and, where appropriate, FDA approval. Before GestVision, Wendy held positions at: HistoRx, Inc, a biotechnology company delivering diagnostic solutions to guide treatment decisions in oncology (acquired by Novartis); Curagen Corporation, University of South Florida and Moffitt Cancer Center; and Cytogen Corp. Wendy holds an MBA from Yale University and a BA from Swarthmore College.

  • Emily Moore, MPH 

    VP of Business and Commercial Operations
    Emily has over 20 years’ experience in creating and implementing growth strategies, leading the process from strategy development to execution of profitable business plans. Over the last 15 years, Emily has focused her career on bringing disruptive healthcare innovations to market to improve patient access and drive down the cost of care. Before GestVision, Emily held positions at Temptime Corporation, Magellan Health and Praxair, Inc. Emily holds an MPH from Columbia University and a BA from Wellesley College.

  • Hugh Fryer, PhD

    Vice President of Research and Development
    Hugh has over 30 years’ experience in research and management related to clinical therapeutics and diagnostics. Before GestVision, Hugh held positions with Sekisui Diagnostics, American Diagnostica, and Curagen as a strategic leader responsible for developing new product portfolio pipelines. He has led R&D sites located in the US, and abroad. He holds a PhD from Yale University and a BS from the University of California San Diego.